(Q40572114)

21 September 2017

1 reference

title

The androgenicity of progestins (English)

1 reference

21 September 2017

P D Darney

1

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 January 1995

1 reference

American Journal of Medicine

21 September 2017

published in

1 reference

21 September 2017

volume

98

1 reference

21 September 2017

issue

1A

1 reference

21 September 2017

page(s)

104S-110S

1 reference

Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Progestogens and arterial disease--evidence from the Royal College of General Practitioners' study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Cardiovascular death among women under 40 years of age using low-estrogen oral contraceptives and intrauterine devices in Finland from 1975 to 1984.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

New progestogens in oral contraception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Effect of two oral contraceptives containing 30 micrograms ethinylestradiol and 75 micrograms gestodene or 150 micrograms desogestrel upon various hormonal parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Binding of progestagens to receptor proteins in MCF-7 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Clinical and hormonal effects of two contraceptives: Correlation to serum concentrations of levonorgestrel and gestodene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Oral contraceptives containing desogestrel in the maintenance of the remission of hirsutism: Monthly versus bimonthly treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

The efficacy and tolerability of norgestimate/ethinyl estradiol (250 μg of norgestimate/35 μg of ethinyl estradiol): Results of an open, multicenter study of 59,701 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Gestoden, an innovative progestogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

The interaction between sex hormone binding globulin and levonorgestrel released from Norplant, an implantable contraceptive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Clinical results with subcutaneous implants containing 3-keto desogestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

The effect of triphasic oral contraceptives on plasma lipids and lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Metabolic changes during treatment with two different progestogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Clinical acceptability of monophasic gestodene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multicenter trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

inferred from DOI database lookup

7 January 2021

based on heuristic

A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980067-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(99)80067-9

1 reference

21 September 2017

1 reference